There is good news for patients suffering from locally advanced or metastatic non-small cell lung cancer! Alimta, Eli Lilly & Co.'s chemotherapy, has managed to pass the second of the third step, by earning the funding from United Kingdom's National Health Service.

This comes as blessing to the patients because Alimta has been recommended by United Kingdom's National Institute for Health and Clinical Excellence or NICE, a special health authority of NHS. Alimta is being recommended as a maintenance treatment of locally advanced or metastatic non-small cell lung cancer patients.

Such approved drugs are much needed as lung cancer is one of the most common types of cancer. Lung cancer costs 1.3 million lives worldwide every year. This dreadful disease can prove fatal if the cancer causing cells manage to seep into the bones, liver and brain through the bloodstream.

Alimta was also recommended earlier by NICE, but the earlier approval passed it as a first-line treatment to be used in combination with cisplatin for locally advanced and metastatic non-small cell lung cancer.

The therapy was for the patients with other than predominantly squamous cell histology, and as a cure for metastatic pleural mesothelioma.

Alimta has cleared many tests, one included approval by European Commission in July 2009. Another backing Alimta received was from U. S. Food and Drug Administration in July 2009. FDA supported the Alimta for use in order to continue the effect of treatment initially.

But recommendation from NICE was an important achievement because if the4 chemotherapy was not advised by the NHS's NICE; the patients would have to struggle hard to get the access of the state funding.